Event-related potential correlates of selective processing in early- and continuously-treated children with phenylketonuria: Effects of concurrent phenylalanine level and dietary control

Molecular Genetics and Metabolism

Volumn 99, Issue SUPPL., 2010, Pages

  de Sonneville, Leo M J ^a   Huijbregts, Stephan C J ^a   van Spronsen, Francjan J ^b   Verkerk, Paul H ^c   Sergeant, Joseph A ^d   Licht, Robert ^d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c TNO   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Dietary control; ERP; Information processing; Lifetime Phe; Phenylketonuria; Selective attention

Indexed keywords

PHENYLALANINE;

ADOLESCENT; ARTICLE; BLOOD LEVEL; BRAIN MATURATION; CHILD; CONTROLLED STUDY; DIET RESTRICTION; EARLY INTERVENTION; EVENT RELATED POTENTIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCEPTION; PHENYLKETONURIA; PRIORITY JOURNAL; SCHOOL CHILD; SELECTIVE ATTENTION; TASK PERFORMANCE;

EID: 72249084119     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.177     Document Type: Article

References (41)

1. van Spronsen F.J., Hoeksma M., and Reijngoud D.J. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?. J. Inherit. Metab. Dis. 32 (2009) 46-51
2. Burgard P. Development of intelligence in early treated phenylketonuria. Eur. J. Pediatr. 159 Suppl. 2 (2000) S74-S79
3. DeRoche K., and Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev. Neuropsychol. 33 (2008) 474-504
4. VanZutphen K.H., Packman W., Sporri L., Needham M.C., Morgan C., Weisiger K., and Packman S. Executive functioning in children and adolescents with phenylketonuria. Clin. Genet. 72 (2007) 13-18
5. Christ S.E., Moinuddin A., McKinstry R.C., DeBaun M., and White D.A. Inhibitory control in children with frontal infarcts related to sickle cell disease. Child Neuropsychol. 13 (2007) 132-141
6. Diamond A., Prevor M.B., Callender G., and Druin D.P. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr. Soc. Res. Child Dev. 62 (1997) (4, Serial No. 252)
7. Griffiths P., Tarrini M., and Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria: correlation with historical and concurrent phenylalanine levels. J. Intellect. Disabil. Res. 41 (1997) 317-323
8. Leuzzi V., Pansini M., Sechi E., Chiarotti F., Carducci C., Levi G., and Antonozzi I. Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 27 (2004) 115-125
9. Welsh M.C., Pennington B.F., Ozonoff S., Rouse B., and McCabe E.R.B. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev. 61 (1990) 1697-1713
10. White D.A., Nortz M.J., Mandernach T., Huntington K., and Steiner R.D. Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J. Int. Neuropsychol. Soc. 8 (2002) 1-11
11. Azadi B., Seddigh A., Tehrani-Doost M., Alaghband-Rad J., and Ashrafi M.R. Executive dysfunction in treated phenylketonuric patients. Eur. Child Adolesc. Psychiatry 18 (2009) 360-368
12. Gourovitch M.L., Craft S., Dowton S.B., Ambrose P., and Sparta S. Interhemispheric transfer in children with early-treated phenylketonuria. J. Clin. Exp. Neuropsychol. 16 (1994) 393-404
13. Mazzocco M.M., Nord A.M., Van Doorninck W.J., Greene C.L., Kovar C.G., and Pennington B.F. Cognitive development among children with early-treated phenylketonuria. Dev. Neuropsychol. 10 (1994) 133-151
14. Schmidt E., Burgard P., and Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur. J. Pediatr. 155 Suppl. 1 (1996) S82-S86
15. Weglage J., Pietsch M., Funders B., Koch H.G., and Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria: result of impaired frontal lobe functions?. Eur. J. Pediatr. 155 (1996) 200-204
16. Weglage J., Schmidt E., Funders B., Pietsch M., and Ullrich K. Sustained attention in untreated non-PKU-hyperphenylalanaemia. J. Clin. Exp. Neuropsychol. 18 (1996) 343-348
17. De Sonneville L.M.J., Schmidt E., Michel U., and Batzler U. Preliminary neuropsychological test results. Eur. J. Pediatr. 149 Suppl. 1 (1990) S39-S44
18. Huijbregts S.C.J., De Sonneville L.M.J., Licht R., Van Spronsen F.J., Verkerk P.H., and Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40 (2002) 7-15
19. Huijbregts S.C.J., De Sonneville L.M.J., Van Spronsen F.J., Licht R., and Sergeant J.A. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci. Biobehav. Rev. 26 (2002) 697-712
20. Albrecht J., Garbade S.F., and Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 33 (2008) 414-421
21. Leuzzi V., Seri S., Cerquiglini A., Carducci CL., Carducci Ca., and Antonozzi I. Derangement of the dopaminergic system in phenylketonuria: study of the event-related potential (P300). J. Inherit. Metab. Dis. 23 (2000) 317-320
22. Diamond A. A model system for studying the role of dopamine in the prefrontal cortex during early development in humans: early and continuously treated phenylketonuria. In: Nelson C.A., and Luciana M. (Eds). Handbook of Developmental Cognitive Neuroscience (2001), MIT Press, Cambridge, Massachusetts
23. Bick U., Fahrendorf G., Ludolph A.C., Vassalo P., Weglage J., and Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur. J. Pediatr. 150 (1991) 185-189
24. Bick U., Ullrich K., Stober U., Moller H., Schuierer G., Ludolph A.C., Oberwittler C., Weglage J., and Wendel U. White matter abnormalities in patient with treated hyperphenylalanaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur. J. Pediatr. 152 (1993) 1012-1020
25. Cleary M.A., Walter J.H., Jenkins J.P., Alani S.M., Tyler K., and Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344 (1994) 87-90
26. Thompson A.J., Tillotson S., Smith I., Kendall B., Moore S.G., and Brenton D.P. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 116 (1993) 811-821
27. Weglage J., Bick U., Schuierer G., Pietsch M., Sprinz A., Zab R., and Ullrich K. Progression of cerebral white matter abnormalities in early-treated patients with phenylketonuria during adolescence. Neuropediatrics 28 (1997) 239-240
28. Scarabino T., Popolizio T., Tosetti M., Montanaro D., Giannatempo G.M., Terlizzi R., Pollice S., Maiorana A., Maggialetti N., Carriero A., Leuzzi V., and Salvolini U. Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol. Med. 114 (2009) 461-474
29. Leuzzi V., Tosetti M., Montanaro D., Carducci C., Artiola C., Carducci C., Antonozzi I., Burroni M., Carnevale F., Chiarotti F., Popolizio T., Giannatempo G.M., D'Alesio V., and Scarabino T. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J. Inherit. Metab. Dis. 30 (2007) 209-216
30. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Warwick L., Casanelia S., Anderson V.A., and Boneh A. Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev. Med. Child Neurol. 46 (2004) 230-238
31. Henderson R.M., McCulloch D.L., Herbert A.M., Robinson P.H., and Taylor M.J. Visual event-related potentials in children with phenylketonuria. Acta. Paediatr. 89 (2000) 52-57
32. Pietz J., Schmidt E., Matthis P., Kobialka B., Kutscha A., and De Sonneville L.M.J. EEGs in phenylketonuria. I: follow-up to adulthood; II: short-term diet-related changes in EEGs and cognitive function. Dev. Med. Child Neurol. 35 (1993) 54-64
33. Pueschel S.M., Fogelson-Doyle L., Kammerer B., and Matsumiya Y. Neurophysiological, psychological, and nutritional investigations during discontinuation of the phenylalanine-restricted diet in children with classic phenylketonuria. J. Ment. Defic. Res. 27 (1983) 61-67
34. Giovannini M., Valsasina R., Villani R., Ducati A., Riva E., Landi A., and Longhi R. Pattern reversal visual evoked potentials in phenylketonuria. J. Inherit. Met. Dis. 11 (1988) 416-421
35. Pietz J., Kreis R., Rupp A., Mayatepek E., Rating D., Boesch C., and Bremer H.J. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest. 103 (1999) 1169-1178
36. Beringer J. Experimental Run Time Systems (1996), BeriSoft Cooperation, Frankfurt am Main, Germany
37. Kenemans J.L., Smulders F.T., and Kok A. Selective processing of two-dimensional visual stimuli in young and old subjects: electrophysiological analysis. Psychophysiology 32 (1995) 108-120
38. Stevens J. Applied Multivariate Statistics for the Social Sciences (1996), Lawrence Erlbaum Associates, Mahwah, New Jersey
39. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1988), Lawrence Erlbaum Associates, Hillsdale, NJ
40. Diamond A., and Herzberg C. Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. Brain 119 (1996) 523-538
41. Ullrich K., Weglage J., Oberwittler C., Pietsch M., Funders B., and Eckhardstein H.V. Effect of l-Dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients. Eur. J. Pediatr. 155 Suppl. 1 (1996) S74-S77